Repligen Corp
Could not find a ticker for this position, may be a filing error
A maker of tools and consumables for biologic drug manufacturing, Repligen supplies cell-retention filters, pre-packed columns, purification resins, and growth factors used by drugmakers worldwide. Founded in 1981 in Cambridge, Massachusetts, by two molecular biology professors, it focused entirely on bioprocessing starting in 2012. Its name blends "replication" and "genetics," a nod to its roots in recombinant protein science.
1.00% Convertible Senior Notes due December 15, 2028
Granted 995 · Sold 275
Granted 48.0K · Sold 74.1K
Granted 29.6K · Sold 16.3K
Granted 6.8K
Granted 7.9K · Sold 2.2K
Granted 5.4K
Granted 7.8K · Sold 733
Granted 995
Granted 2.3K
Granted 995
Granted 995
Granted 995
Granted 4.1K
Granted 995
Granted 995
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Dawes Karen ADirector · 2 transactions | +0.8% | 92.8K | 995 | — | 275 |
| Hunt AnthonyDirector · 23 transactions | -19.1% | 89.1K | 48.0K | — | 74.1K |
| Loeillot OlivierChief Executive Officer, Director · 9 transactions | +16.2% | 54.2K | 29.6K | — | 16.3K |
| Muir Glenn PDirector · 3 transactions | +20.4% | 40.1K | 6.8K | — | — |
| Bylund JamesChief Operating Officer · 6 transactions | +7.2% | 25.4K | 7.9K | — | 2.2K |
| Kuriyel RalfSenior VP, R&D · 5 transactions | +24.9% | 20.1K | 5.4K | — | — |
| Garland Jason KCFO · 5 transactions | +40.3% | 19.4K | 7.8K | — | 733 |
| Madaus Martin DDirector · 1 transaction | +7.7% | 14.0K | 995 | — | — |
| Douglass Brian RobbCHIEF PRODUCT OFFICER · 3 transactions | — | 8.0K | 2.3K | — | — |
| Eglinton Manner CarrieDirector · 1 transaction | +22.3% | 5.5K | 995 | — | — |
| Barthelemy NicolasDirector · 1 transaction | +22.4% | 5.4K | 995 | — | — |
| Mhatre RohinDirector · 1 transaction | +24.8% | 5.0K | 995 | — | — |
| Hughes ViolettaCHIEF ACCOUNTING OFFICER · 1 transaction | — | 4.1K | 4.1K | — | — |
| Konstantinov KonstantinDirector · 1 transaction | +34.4% | 3.9K | 995 | — | — |
| Pax MargaretDirector · 1 transaction | +49.4% | 3.0K | 995 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -93.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.